دورية أكاديمية
أعرض في EDS

Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.

التفاصيل البيبلوغرافية
العنوان: Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.
المؤلفون: Beigi YZ; Laboratory of System Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran., Lanjanian H; Software Engineering Department, Engineering Faculty, Istanbul Topkapi University, Istanbul, Turkey., Fayazi R; Laboratory of System Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran., Salimi M; Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran., Hoseyni BHM; Laboratory of System Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran., Noroozizadeh MH; Negah Eye Hospital, Tehran, Iran., Masoudi-Nejad A; Laboratory of System Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. amasoudin@ut.ac.ir.
المصدر: Molecular biomedicine [Mol Biomed] 2024 May 10; Vol. 5 (1), pp. 17. Date of Electronic Publication: 2024 May 10.
نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Singapore Country of Publication: Singapore NLM ID: 9918283581406676 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-8651 (Electronic) Linking ISSN: 26628651 NLM ISO Abbreviation: Mol Biomed Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Singapore : Springer Singapore, [2020]-
مواضيع طبية MeSH: Melanoma*/genetics , Melanoma*/pathology , Melanoma*/therapy , Melanoma*/drug therapy , Molecular Targeted Therapy*/methods , Genetic Heterogeneity* , Uveal Neoplasms*/genetics , Uveal Neoplasms*/therapy , Uveal Neoplasms*/pathology, Humans ; Neoplastic Cells, Circulating/metabolism ; Neoplastic Cells, Circulating/pathology ; Biomarkers, Tumor/genetics ; Mutation ; Circulating Tumor DNA/genetics ; Circulating Tumor DNA/blood ; Liquid Biopsy/methods
مستخلص: Uveal cancer (UM) offers a complex molecular landscape characterized by substantial heterogeneity, both on the genetic and epigenetic levels. This heterogeneity plays a critical position in shaping the behavior and response to therapy for this uncommon ocular malignancy. Targeted treatments with gene-specific therapeutic molecules may prove useful in overcoming radiation resistance, however, the diverse molecular makeups of UM call for a patient-specific approach in therapy procedures. We need to understand the intricate molecular landscape of UM to develop targeted treatments customized to each patient's specific genetic mutations. One of the promising approaches is using liquid biopsies, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), for detecting and monitoring the disease at the early stages. These non-invasive methods can help us identify the most effective treatment strategies for each patient. Single-cellular is a brand-new analysis platform that gives treasured insights into diagnosis, prognosis, and remedy. The incorporation of this data with known clinical and genomics information will give a better understanding of the complicated molecular mechanisms that UM diseases exploit. In this review, we focused on the heterogeneity and molecular panorama of UM, and to achieve this goal, the authors conducted an exhaustive literature evaluation spanning 1998 to 2023, using keywords like "uveal melanoma, "heterogeneity". "Targeted therapies"," "CTCs," and "single-cellular analysis".
(© 2024. The Author(s).)
References: Mol Cancer Ther. 2013 May;12(5):768-76. (PMID: 23443802)
JAMA Ophthalmol. 2020 Feb 1;138(2):188-189. (PMID: 31895426)
Clin Cancer Res. 2020 Apr 15;26(8):1886-1895. (PMID: 32015020)
Exp Mol Med. 2022 Oct;54(10):1670-1694. (PMID: 36224343)
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Dec;164(4):401-409. (PMID: 31544901)
Front Pharmacol. 2023 Sep 26;14:1264345. (PMID: 37822877)
Cancers (Basel). 2021 Nov 02;13(21):. (PMID: 34771666)
Ann Clin Lab Sci. 2013 Summer;43(3):295-304. (PMID: 23884225)
Invest Ophthalmol Vis Sci. 2014 Jun 26;55(7):4395-404. (PMID: 24970258)
Acta Pharmacol Sin. 2015 Oct;36(10):1219-27. (PMID: 26388155)
Curr Oncol. 2023 Jul 03;30(7):6374-6396. (PMID: 37504330)
Invest Ophthalmol Vis Sci. 2020 May 11;61(5):12. (PMID: 32396633)
Cancer Discov. 2017 Oct;7(10):1088-1097. (PMID: 28733428)
Nat Commun. 2018 Nov 9;9(1):4719. (PMID: 30413715)
Aging (Albany NY). 2023 Mar 14;15(6):2082-2096. (PMID: 36920166)
Ophthalmologica. 1998;212(1):80. (PMID: 9438593)
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):658-65. (PMID: 19797220)
JCO Precis Oncol. 2018 May 17;2:. (PMID: 32913999)
Nat Commun. 2020 Oct 2;11(1):4965. (PMID: 33009371)
Eur Urol. 2020 Feb;77(2):170-177. (PMID: 31648903)
J Transl Med. 2012 Sep 15;10:192. (PMID: 22978632)
Invest Ophthalmol Vis Sci. 2014 Jun 26;55(8):5160-7. (PMID: 24970262)
Transl Vis Sci Technol. 2020 Sep 01;9(2):50. (PMID: 32953248)
Oncotarget. 2015 Dec 29;6(42):44623-34. (PMID: 26556851)
Cancer Discov. 2021 Apr;11(4):858-873. (PMID: 33811121)
Front Immunol. 2023 Aug 18;14:1225140. (PMID: 37662962)
Hum Vaccin Immunother. 2022 May 31;18(3):2034377. (PMID: 35258435)
Br J Ophthalmol. 1998 Feb;82(2):199-200. (PMID: 9613393)
Br J Cancer. 2023 Sep;129(5):772-781. (PMID: 37443346)
Nat Commun. 2021 Jan 11;12(1):227. (PMID: 33431814)
Ocul Immunol Inflamm. 2010 Apr;18(2):80-90. (PMID: 20370332)
Pharmaceutics. 2021 Aug 25;13(9):. (PMID: 34575410)
Nat Rev Cancer. 2019 Jul;19(7):377-391. (PMID: 31209265)
Clin Cancer Res. 2004 Mar 1;10(5):1605-12. (PMID: 15014010)
J Pathol. 2020 Apr;250(4):420-439. (PMID: 31960425)
Transl Vis Sci Technol. 2019 Apr 17;8(2):18. (PMID: 31024753)
Cancers (Basel). 2021 Dec 28;14(1):. (PMID: 35008296)
Arch Pathol Lab Med. 2018 Feb;142(2):198-207. (PMID: 29144792)
Cancer Cell. 2018 Jan 8;33(1):151. (PMID: 29316429)
Nat Rev Genet. 2016 Mar;17(3):175-88. (PMID: 26806412)
Chin Clin Oncol. 2018 Feb;7(1):8. (PMID: 29486567)
Biomark Res. 2023 Dec 1;11(1):104. (PMID: 38037114)
Eur J Cancer. 2004 Nov;40(16):2389-95. (PMID: 15519510)
Cancers (Basel). 2021 Nov 17;13(22):. (PMID: 34830903)
Mod Pathol. 2018 May;31(5):763-771. (PMID: 29327717)
Arch Pathol Lab Med. 2009 Aug;133(8):1219-22. (PMID: 19653713)
Mol Oncol. 2016 Mar;10(3):371-3. (PMID: 26875532)
J Zhejiang Univ Sci B. 2021 Feb 15;22(2):112-122. (PMID: 33615752)
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. (PMID: 33608497)
Nat Commun. 2020 Apr 20;11(1):1894. (PMID: 32313009)
Br J Cancer. 2020 Mar;122(7):1059-1067. (PMID: 32037400)
Eur J Cancer. 2022 Jul;169:146-155. (PMID: 35569281)
Mod Pathol. 2014 Oct;27(10):1321-30. (PMID: 24633195)
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175. (PMID: 29497459)
NPJ Precis Oncol. 2022 Oct 10;6(1):71. (PMID: 36210388)
Arch Ophthalmol. 2009 Aug;127(8):989-98. (PMID: 19667335)
J Pathol Clin Res. 2017 Nov 13;4(1):26-38. (PMID: 29416875)
Cancers (Basel). 2019 Jul 27;11(8):. (PMID: 31357599)
Cold Spring Harb Mol Case Stud. 2021 Oct 19;7(5):. (PMID: 34470851)
Cancer Rep (Hoboken). 2021 Aug;4(4):e1347. (PMID: 33535273)
Cancer Gene Ther. 2022 Dec;29(12):1807-1808. (PMID: 36456705)
Nat Med. 2019 May;25(5):744-750. (PMID: 31011206)
Ocul Oncol Pathol. 2020 Dec;6(6):381-387. (PMID: 33447587)
Ophthalmology. 2015 Mar;122(3):600-9. (PMID: 25439431)
Front Immunol. 2023 Jan 30;14:1099071. (PMID: 36793711)
Cancers (Basel). 2021 Dec 25;14(1):. (PMID: 35008260)
Curr Med Chem. 2024 Jan 03;:. (PMID: 38173196)
Cancer Discov. 2014 Jun;4(6):650-61. (PMID: 24801577)
Sci Rep. 2021 Feb 16;11(1):3876. (PMID: 33594192)
Front Mol Biosci. 2021 Jan 06;7:611584. (PMID: 33585560)
Cancer Discov. 2016 May;6(5):479-91. (PMID: 26969689)
BMC Cancer. 2023 Mar 27;23(1):277. (PMID: 36973672)
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3464-3470. (PMID: 28700778)
Ann Transl Med. 2014 Nov;2(11):107. (PMID: 25489581)
J Pathol. 2001 Jun;194(2):201-6. (PMID: 11400149)
Nat Rev Genet. 2015 Dec;16(12):716-26. (PMID: 26460349)
Front Immunol. 2021 Jul 30;12:701636. (PMID: 34394096)
Eye (Lond). 2007 Jun;21(6):752-9. (PMID: 16575415)
Pigment Cell Melanoma Res. 2016 Sep;29(5):583-9. (PMID: 27390171)
Innovation (Camb). 2022 May 06;3(4):100259. (PMID: 35647572)
Int J Cancer. 2014 Mar 1;134(5):1207-13. (PMID: 23934701)
Genome Res. 2021 Oct;31(10):1794-1806. (PMID: 34301624)
Cancers (Basel). 2019 Apr 05;11(4):. (PMID: 30959764)
Exp Eye Res. 2022 Oct;223:109214. (PMID: 35981602)
Int J Oncol. 2020 Dec;57(6):1262-1279. (PMID: 33173970)
Cancers (Basel). 2020 Sep 30;12(10):. (PMID: 33008022)
Am J Ophthalmol. 2018 Nov;195:154-160. (PMID: 30092184)
Crit Rev Oncol Hematol. 2024 Jan;193:104218. (PMID: 38040071)
Ocul Oncol Pathol. 2020 Oct;6(5):360-367. (PMID: 33123530)
Exp Mol Med. 2023 Nov;55(11):2433-2444. (PMID: 37907747)
Cancers (Basel). 2023 Jan 26;15(3):. (PMID: 36765733)
Cancers (Basel). 2021 Nov 28;13(23):. (PMID: 34885099)
Diagnostics (Basel). 2021 May 27;11(6):. (PMID: 34071824)
Eur J Cancer. 2022 Jul;170:27-41. (PMID: 35580369)
Mol Cancer. 2020 Feb 25;19(1):37. (PMID: 32098629)
Nat Rev Cancer. 2019 Oct;19(10):553-567. (PMID: 31455893)
Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):65-70. (PMID: 30122851)
Methods Mol Biol. 2014;1102:427-40. (PMID: 24258991)
Front Pharmacol. 2023 Feb 09;14:1138452. (PMID: 36843929)
Nat Commun. 2020 Jan 24;11(1):496. (PMID: 31980621)
Cancer Treat Rev. 2020 Nov;90:102091. (PMID: 32877777)
BMC Cancer. 2013 Aug 05;13:371. (PMID: 23915344)
Cancers (Basel). 2022 Jun 22;14(13):. (PMID: 35804836)
BMC Cancer. 2017 May 3;17(1):311. (PMID: 28468669)
Cell Rep. 2023 Sep 26;42(9):113132. (PMID: 37708024)
Cell Res. 2014 Jun;24(6):701-12. (PMID: 24699064)
Front Immunol. 2019 Nov 05;10:2525. (PMID: 31787967)
Clin Cancer Res. 2009 Feb 1;15(3):1032-8. (PMID: 19188176)
Biomedicines. 2017 Dec 08;5(4):. (PMID: 29292745)
Arch Ophthalmol. 2008 Mar;126(3):416-9. (PMID: 18332325)
Mol Immunol. 2014 Apr;58(2):182-6. (PMID: 24370793)
Nat Mater. 2016 Jun;15(6):621-7. (PMID: 27019384)
Nat Biotechnol. 2013 Jun;31(6):539-44. (PMID: 23609047)
Cancer Cell. 2020 Apr 13;37(4):471-484. (PMID: 32289271)
Front Cell Dev Biol. 2021 Feb 22;9:639233. (PMID: 33693004)
Clin Cancer Res. 2019 Apr 1;25(7):2194-2205. (PMID: 30385653)
Prog Retin Eye Res. 2021 Nov;85:100968. (PMID: 33852963)
Ophthalmic Res. 2020;63(3):358-368. (PMID: 31614358)
Cancer Res. 2004 Jan 1;64(1):128-34. (PMID: 14729616)
Exp Ther Med. 2021 Dec;22(6):1428. (PMID: 34707709)
Melanoma Res. 2008 Jun;18(3):191-200. (PMID: 18477893)
Acta Ophthalmol. 2023 Feb;101(1):34-48. (PMID: 35801361)
Hum Mol Genet. 2015 Oct 15;24(R1):R74-84. (PMID: 26113645)
Invest Ophthalmol Vis Sci. 2013 Aug 23;54(8):5721-9. (PMID: 23821189)
Mod Pathol. 2017 Mar;30(3):350-356. (PMID: 27934878)
Klin Oczna. 1972;42(2):699-703. (PMID: 5022208)
Acta Ophthalmol. 2015 Feb;93(1):59-66. (PMID: 25613126)
J Hypertens. 2017 Sep;35(9):1727-1741. (PMID: 28767484)
Melanoma Res. 2005 Dec;15(6):503-7. (PMID: 16314735)
Cancer Metastasis Rev. 2017 Mar;36(1):109-140. (PMID: 28229253)
Int J Mol Sci. 2018 Sep 21;19(10):. (PMID: 30248975)
BMC Cancer. 2018 Dec 17;18(1):1262. (PMID: 30558566)
Eur J Med Res. 2011 Feb 24;16(2):71-5. (PMID: 21463985)
Nat Med. 2019 Oct;25(10):1549-1559. (PMID: 31591606)
Acta Ophthalmol Scand. 2002 Feb;80(1):25-31. (PMID: 11906300)
EBioMedicine. 2023 May;91:104564. (PMID: 37094467)
Genes Chromosomes Cancer. 2001 Mar;30(3):267-73. (PMID: 11170284)
Mol Cell. 2019 Jul 11;75(1):7-12. (PMID: 31299208)
Nat Commun. 2017 May 05;8:15081. (PMID: 28474673)
Am J Ophthalmol. 2016 Feb;162:28-34.e1. (PMID: 26556006)
Int J Oncol. 2021 Apr;58(4):. (PMID: 33649778)
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. (PMID: 29115304)
Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47. (PMID: 25113308)
Nat Commun. 2022 Oct 11;13(1):5988. (PMID: 36220826)
Eye (Lond). 2017 Feb;31(2):241-257. (PMID: 27911450)
Cancers (Basel). 2020 Dec 11;12(12):. (PMID: 33322354)
J Exp Med. 1999 Nov 1;190(9):1197-200. (PMID: 10544192)
J Natl Cancer Inst. 2022 Feb 7;114(2):302-309. (PMID: 34424336)
Genome Res. 2017 Aug;27(8):1287-1299. (PMID: 28546418)
Immunity. 2018 Apr 17;48(4):812-830.e14. (PMID: 29628290)
Front Genet. 2019 Apr 05;10:317. (PMID: 31024627)
Oncotarget. 2017 Jan 3;8(1):846-862. (PMID: 27903987)
Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):186-196. (PMID: 28399342)
Nat Rev Clin Oncol. 2023 Feb;20(2):99-115. (PMID: 36600005)
Cancer. 2016 Aug 1;122(15):2299-312. (PMID: 26991400)
Cancer Cell. 2020 Apr 13;37(4):456-470. (PMID: 32289270)
Mol Biomed. 2021 Aug 20;2(1):25. (PMID: 35006486)
Int J Mol Sci. 2023 Jul 04;24(13):. (PMID: 37446253)
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4898-905. (PMID: 20484589)
Clin Cancer Res. 2008 Jul 15;14(14):4469-74. (PMID: 18628461)
Nat Commun. 2019 Jan 22;10(1):380. (PMID: 30670690)
Nat Rev Dis Primers. 2020 Apr 9;6(1):24. (PMID: 32273508)
Acta Pharmacol Sin. 2021 Feb;42(2):179-188. (PMID: 32601365)
Trends Mol Med. 2021 May;27(5):482-500. (PMID: 33500194)
Cancer Gene Ther. 2022 Oct;29(10):1384-1393. (PMID: 35352024)
Anal Chem. 2023 Mar 21;95(11):5095-5108. (PMID: 36812415)
Cancers (Basel). 2020 Nov 06;12(11):. (PMID: 33172021)
Science. 1976 Oct 1;194(4260):23-8. (PMID: 959840)
Ther Adv Med Oncol. 2020 Oct 22;12:1758835920965852. (PMID: 33149769)
Prog Retin Eye Res. 2022 Sep;90:101041. (PMID: 34999237)
Sci Rep. 2022 Jan 7;12(1):42. (PMID: 34997020)
Oncogene. 2018 Nov;37(47):6136-6151. (PMID: 29995873)
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4254-62. (PMID: 18552379)
Cancers (Basel). 2019 Jul 30;11(8):. (PMID: 31366043)
Ophthalmology. 2012 Aug;119(8):1596-603. (PMID: 22521086)
Cancers (Basel). 2021 Feb 26;13(5):. (PMID: 33652649)
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):151-161. (PMID: 28110020)
EBioMedicine. 2015 Sep 18;2(11):1821-6. (PMID: 26870807)
Front Endocrinol (Lausanne). 2023 Mar 23;14:1163046. (PMID: 37033251)
Cancer. 1998 Oct 15;83(8):1664-78. (PMID: 9781962)
Acta Ophthalmol. 2011 Feb;89(1):17-24. (PMID: 21272286)
Cell. 2021 Oct 14;184(21):5482-5496.e28. (PMID: 34597583)
Ophthalmol Sci. 2023 Mar 11;3(3):100297. (PMID: 37193315)
Cancers (Basel). 2021 Sep 03;13(17):. (PMID: 34503258)
Cell Res. 2012 Mar;22(3):457-72. (PMID: 22357481)
Cancer. 2018 Jul 1;124(13):2693-2703. (PMID: 29579316)
Cancers (Basel). 2022 Jun 23;14(13):. (PMID: 35804863)
Cancers (Basel). 2019 Jun 18;11(6):. (PMID: 31216772)
Crit Rev Oncol Hematol. 2019 Feb;134:39-45. (PMID: 30771872)
Blood. 2019 Aug 22;134(8):709-712. (PMID: 31292111)
Front Oncol. 2022 Apr 11;12:828112. (PMID: 35480119)
Trends Biotechnol. 2020 May;38(5):497-518. (PMID: 31980301)
Invest Ophthalmol Vis Sci. 2013 Jul 10;54(7):4648-58. (PMID: 23761088)
Br J Cancer. 2022 Jun;126(11):1511-1528. (PMID: 35190695)
Nat Commun. 2018 Jan 9;9(1):116. (PMID: 29317634)
Br J Ophthalmol. 2015 Nov;99(11):1550-3. (PMID: 25904122)
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17947-52. (PMID: 25425670)
Oncol Lett. 2021 Jan;21(1):9. (PMID: 33240415)
Br J Cancer. 1995 Jul;72(1):155-9. (PMID: 7599046)
Appl Clin Genet. 2016 Sep 06;9:147-55. (PMID: 27660484)
Biochem Biophys Res Commun. 2017 Oct 7;492(1):18-26. (PMID: 28821433)
Cell Rep. 2014 Sep 25;8(6):1905-1918. (PMID: 25242334)
Br J Cancer. 2014 Sep 23;111(7):1373-80. (PMID: 25058347)
Cancers (Basel). 2023 Jan 04;15(2):. (PMID: 36672282)
Biology (Basel). 2023 May 19;12(5):. (PMID: 37237550)
Genome Biol. 2023 Aug 1;24(1):177. (PMID: 37528411)
Surv Ophthalmol. 2021 Jul-Aug;66(4):552-559. (PMID: 33400941)
Radiat Oncol J. 2020 Sep;38(3):162-169. (PMID: 33012143)
Front Immunol. 2022 Jul 05;13:898925. (PMID: 35865532)
J Vis Exp. 2017 Feb 17;(120):. (PMID: 28287554)
Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3703-7. (PMID: 16936076)
BMC Res Notes. 2015 Sep 17;8:452. (PMID: 26383622)
BMC Cancer. 2021 Sep 29;21(1):1068. (PMID: 34587931)
Surv Ophthalmol. 2024 Mar-Apr;69(2):190-197. (PMID: 37406779)
Genome Res. 2018 Sep;28(9):1353-1363. (PMID: 30061114)
Int J Mol Sci. 2021 Jun 23;22(13):. (PMID: 34201614)
J Invest Dermatol. 2017 Sep;137(9):2033-2035. (PMID: 28499758)
Prog Retin Eye Res. 2020 Mar;75:100800. (PMID: 31563544)
Clin Chem. 2020 Apr 1;66(4):606-613. (PMID: 32176763)
BMC Ophthalmol. 2023 Aug 10;23(1):354. (PMID: 37563735)
Genes Chromosomes Cancer. 2019 Apr;58(4):219-232. (PMID: 30382599)
Cancers (Basel). 2014 Feb 07;6(1):323-32. (PMID: 24514165)
Int J Mol Sci. 2015 Jul 24;16(8):16897-919. (PMID: 26213926)
Melanoma Res. 2015 Oct;25(5):447-9. (PMID: 26086698)
Cancers (Basel). 2020 Apr 23;12(4):. (PMID: 32340176)
Signal Transduct Target Ther. 2021 May 31;6(1):201. (PMID: 34054126)
Nat Cancer. 2022 Apr;3(4):505-517. (PMID: 35469013)
Cancer Res. 2014 Aug 1;74(15):4196-207. (PMID: 24934811)
J Clin Med. 2022 Dec 01;11(23):. (PMID: 36498730)
JAMA Ophthalmol. 2016 Jul 1;134(7):728-33. (PMID: 27123562)
Nat Rev Cancer. 2006 Feb;6(2):146-55. (PMID: 16491074)
Melanoma Res. 2010 Aug;20(4):303-10. (PMID: 20442676)
Oncology. 2011;80(1-2):57-62. (PMID: 21625180)
Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):88-110. (PMID: 26758786)
Int J Mol Sci. 2020 Dec 08;21(24):. (PMID: 33302435)
Cell. 2022 Jan 6;185(1):184-203.e19. (PMID: 34963056)
Oncotarget. 2016 Sep 20;7(38):62754-62766. (PMID: 27517159)
Int J Mol Sci. 2020 Dec 17;21(24):. (PMID: 33348918)
Cancers (Basel). 2013 Dec 10;5(4):1691-738. (PMID: 24335964)
J Invest Dermatol. 2015 Aug;135(8):2040-2048. (PMID: 25830652)
Invest Ophthalmol Vis Sci. 2012 Aug 09;53(9):5370-8. (PMID: 22743317)
Int J Ophthalmol. 2016 Aug 18;9(8):1215-25. (PMID: 27588278)
Cancer Res. 2006 May 1;66(9):4602-9. (PMID: 16651410)
Cancers (Basel). 2019 Jun 20;11(6):. (PMID: 31226786)
Clin Cancer Res. 2007 Feb 15;13(4):1171-8. (PMID: 17317826)
Ophthalmology. 2011 Sep;118(9):1881-5. (PMID: 21704381)
Int J Biol Sci. 2022 Apr 24;18(7):3019-3033. (PMID: 35541919)
Nat Med. 2019 Dec;25(12):1928-1937. (PMID: 31768066)
Ocul Oncol Pathol. 2021 Mar;7(1):17-25. (PMID: 33796512)
Br J Ophthalmol. 2016 Apr;100(4):468-72. (PMID: 26283704)
Middle East Afr J Ophthalmol. 2010 Jul;17(3):210-6. (PMID: 20844676)
فهرسة مساهمة: Keywords: Circulating tumor cells (CTCs); Heterogeneity; Liquid biopsy; Single-cell analysis; Targeted therapy; Uveal melanoma (UM)
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Circulating Tumor DNA)
تواريخ الأحداث: Date Created: 20240509 Date Completed: 20240509 Latest Revision: 20240802
رمز التحديث: 20240802
مُعرف محوري في PubMed: PMC11082128
DOI: 10.1186/s43556-024-00182-2
PMID: 38724687
قاعدة البيانات: MEDLINE
الوصف
تدمد:2662-8651
DOI:10.1186/s43556-024-00182-2